Name
Recombinant Human Angiostatin (Recombinant Human Angiostatin; rHuAngiostatin)；重组人血管抑素
Synonyms
Plasminogen; PLG
Purity
>95% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The specific activity determined by an assay on anti-proliferation and anti-migration using endothelial cells in vitro and anti-angiogenesis in vivo is 5.5×105IU/mg.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μM filtered concentrated solution in 20mM NaAc, pH5.5, 4% mannitol.
Endotoxin
Less than 1EU/μg of rHuAngiostatin as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Background
Angiostatin, is a ~30kDa fragment of plasminogen that is encoded by the PLG gene in humans. It is produced, for example, bybautoproteolytic cleavage of plasminogen, involving extracellular disulfide bond reduction by phosphoglycerate kinase.bFurthermore, angiostatin can be cleaved from plasminogen by different metalloproteinases (MMPs), elastase, prostate-specific antigen (PSA), 13kDa serine protease, or 24kDa endopeptidase. Angiostatin is known to bind many proteins, especially to angiomotin and endothelial cell surface ATP synthase but also integrins, annexin II, C-met receptor, ng2 proteoglycan, tissuetype plasminogen activator, chondroitin sulfate proteoglycans, and CD26. It seems to involve inhibition of endothelial cell migration, proliferation and induction of apoptosis, but its mechanism of action is still unclear. Angiostatin is currently undergoing clinical trials for its use in anticancer therapy. Recombinant angiostatin is expressed in E. coli.
Amino Acid Sequence
VYLSECKTGN GKNYRGTMSK TKNGITCQKW SSTSPHRPRF SPATHPSEGL EENYCRNPDN DPQGPWCYTT DPEKRYDYCD ILECEEECMH CSGENYDGKI SKTMSGLECQ AWDSQSPHAH GYIPSKFPNK NLKKNYCRNP DRELRPWCFT TDPNKRWELC DIPRCTTPPP SSGPTYQCLK GTGENYRGNV AVTVSGHTCQ HWSAQTPHTH NRTPENFPCK NLDENYCRNP DGKRAPWCHT TNSQVRWEYC KIPSCDSSP